Correlation Between Vascular Endothelial Growth Factor and Long-Term Occurrence of HCV-Related Hepatocellular Carcinoma After Treatment with Direct-Acting Antivirals
- 15 July 2021
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 39 (8) , 653-660
Abstract
We aimed to evaluate the correlation between vascular endothelial growth factor (VEGF) and long-term occurrence of hepatocellular carcinoma after HCV treatment with direct-acting antivirals (DAAs) and the HCC stage. Two groups with HCV-related liver cirrhosis and HCC were included: group 1, HCC following DAAs; group 2, HCC did not receive DAAs. The serum level of VEGF and HCC staging was evaluated. The duration between DAAs and HCC was 21.81 ± 11.66 months. Portal vein thrombosis (PVT) was observed more in group 1 (31%). VEGF was relatively elevated in group 1 compared to group 2. HCC patients after DAAs, showed elevated VEGF with frequent PVT.Keywords
This publication has 51 references indexed in Scilit:
- HCC and angiogenesis: possible targets and future directionsNature Reviews Clinical Oncology, 2011
- Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways #Hepatology, 2009
- The neurotransmitter dopamine modulates vascular permeability in the endotheliumJournal of Molecular Signaling, 2008
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006
- The Potential of Angiogenesis Soluble Markers in Chronic Hepatitis C *Hepatology, 2005
- Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in miceGut, 2005
- Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasionJournal of Hepatology, 2004
- Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinomaJournal of Hepatology, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001